Loading
A phase 1/2 trial of Pembrolizumab in melanoma and metastatic cancer, run by CJ Bioscience, Inc., now recruiting.
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05877430 by CJ Bioscience, Inc., with 160 participants planned, started 2023-09-11 and due to reach its primary completion in 2026-07. Interventions recorded: CJRB-101, Pembrolizumab injection. Conditions listed: NSCLC, HNSCC, Melanoma, Metastatic Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/